Literature DB >> 15179312

[Viral uveitis].

B Bodaghi1.   

Abstract

Viral eye diseases are common and associated with different well-known forms of uveitis. However, experimental models and clinical observations have led to an infectious, in particular a viral etiology in different autoimmune conditions. The use of molecular techniques is particularly informative, not only to characterize the previously well-known subgroup of presumed viral uveitis, but also to define the role of these agents or emerging viruses in atypical forms of autoimmune uveitis resistant to conventional therapy. PCR detection of viral DNA in patients with uveitis is a rapid, sensitive and accurate procedure. Therefore, aqueous humor could be analyzed when uveitis is unresponsive to anti-inflammatory molecules, in order to exclude a viral condition and dramatically modify the therapeutic management. Several new viral entities have recently been identified such as cytomegalovirus-associated chronic anterior uveitis and non-necrotizing herpetic retinopathies in immunocompetent hosts. Systemic antiviral drugs should be proposed rapidly in order to control viral replication before the use of corticosteroids. Maintenance therapy based on low-dose antivirals can reduce the rate of recurrence and should be considered.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15179312     DOI: 10.1016/s0181-5512(04)96176-1

Source DB:  PubMed          Journal:  J Fr Ophtalmol        ISSN: 0181-5512            Impact factor:   0.818


  2 in total

1.  Long-term follow-up of herpetic non-necrotizing retinopathy with occlusive retinal vasculitis and neovascularization.

Authors:  Kim Albert; Maureen Masset; Sabine Bonnet; François Willermain; Laure Caspers
Journal:  J Ophthalmic Inflamm Infect       Date:  2015-02-28

Review 2.  Eye and Periocular Skin Involvement in Herpes Zoster Infection.

Authors:  Chris D Kalogeropoulos; Ioannis D Bassukas; Marilita M Moschos; Khalid F Tabbara
Journal:  Med Hypothesis Discov Innov Ophthalmol       Date:  2015
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.